Formulation And Evaluation Of Itraconazole Loaded Solid Lipid Nanoparticles For Tinea Cruris:A Promising Approach To Combat Antifungal Drug Resistance

Authors

  • Hamsa Priya M Student,Department of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India.
  • Chandana M
  • Bharath B
  • Darshan G
  • Sri lekha M
  • Dr. N. Venkatesan

DOI:

https://doi.org/10.37591/rrjodfdp.v10i3.1377

Keywords:

Itraconazole, Nano Formulation, SEM Analysis, Optimization Techniques, Antifungal Drugs.

Abstract

A fungal infection of the skin is among the most prevalent dermatological conditions worldwide. When used topically, gel formulations are among the best dose forms for treating skin infections. A promising method to reach the deeper layers of the skin and improve itraconazole (ITZ) permeability through the stratum corneum is nanotechnology. The production of ITZ-loaded nanoparticles (ITZ NPs) was accomplished through the evaporation emulsion method, and subsequently, these nanoparticles were integrated into a gel utilizing Carbopol 934 as the gelling agent. ITZ NP gel's physical characteristics, in vitro release, ex vivo penetration tests, and antifungal activity were all described. ITZ NPs had colloidal diameters between 200 nm and exhibited a nearly spherical form. The effectiveness of drug encapsulation was 98:79 ± 1:24%. Compared to a gel containing an ITZ-saturated suspension, ITZ NP gel showed a longer ex vivo penetration of ITZ over a 24-hour period via excised rat skin and a greater drug-penetrating capacity. The ITZ-loaded NP integrated gel exhibited superior in vitro antifungal activity compared to the ITZ dispersion. Through transdermal drug administration, the ITZ-loaded nanosystem integrated into gel may improve antifungal activity.

References

Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs. 2001;61 Suppl 1:39-47.

Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304.

Dhiman N., Awasthi R., Sharma B., Kharkwal H., Kulkarni G.T. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9 . https://doi.org/10.3389/fchem.2021.580118

Clinard VB, Smith JD. Cutaneous Fungal Infections. US Pharm. 2015;40(4):35-9.

Sheehan DJ, Hitchcock CA, Sibley CM. Current and Emerging Azole Antifungal Agents. Clin Microbiol Rev. 1999;12(1):40-79.

Pires CA, Cruz NF, Lobato AM, Sousa PO, Carneiro FR, Mendes AM. Clinical, epidemiological, and therapeutic profile of dermatophytosis. An Bras Dermatol. 2014;89(2):259-64.

Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166(5-6):335

How C.W., Rasedee A., Manickam S., Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf. B Biointerfaces. 2013;112:393–399.

Jacob S., Nair A.B., Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater. Res. 2020;24(1):1–16.

Kamboj S., Bala S., Nair A.B. Solid lipid nanoparticles: an effective lipid based technology for poorly water soluble drugs. Int. J. Pharm. Sci. Rev. Res. 2010;5(2):78–90.

Downloads

Published

2024-01-29

Issue

Vol. 10 No. 3 (2023)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.